CN106755296B - Carabin在治疗脂肪肝和Ⅱ型糖尿病中的功能和应用 - Google Patents
Carabin在治疗脂肪肝和Ⅱ型糖尿病中的功能和应用 Download PDFInfo
- Publication number
- CN106755296B CN106755296B CN201611004459.4A CN201611004459A CN106755296B CN 106755296 B CN106755296 B CN 106755296B CN 201611004459 A CN201611004459 A CN 201611004459A CN 106755296 B CN106755296 B CN 106755296B
- Authority
- CN
- China
- Prior art keywords
- carabin
- liver
- mouse
- diabetes
- cre
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611004459.4A CN106755296B (zh) | 2016-11-15 | 2016-11-15 | Carabin在治疗脂肪肝和Ⅱ型糖尿病中的功能和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611004459.4A CN106755296B (zh) | 2016-11-15 | 2016-11-15 | Carabin在治疗脂肪肝和Ⅱ型糖尿病中的功能和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106755296A CN106755296A (zh) | 2017-05-31 |
CN106755296B true CN106755296B (zh) | 2021-04-13 |
Family
ID=58969983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611004459.4A Active CN106755296B (zh) | 2016-11-15 | 2016-11-15 | Carabin在治疗脂肪肝和Ⅱ型糖尿病中的功能和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106755296B (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009114681A2 (en) * | 2008-03-13 | 2009-09-17 | Dharmacon, Inc. | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
WO2013033657A2 (en) * | 2011-09-02 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY |
WO2015177330A1 (en) * | 2014-05-23 | 2015-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of heart failure |
CN104107418A (zh) * | 2014-08-01 | 2014-10-22 | 武汉大学 | Carabin在治疗心肌肥厚中的功能及应用 |
-
2016
- 2016-11-15 CN CN201611004459.4A patent/CN106755296B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN106755296A (zh) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106512014A (zh) | 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 | |
CN107519194B (zh) | miR-21在制备治疗宫腔粘连和/或薄型内膜的药物中的应用 | |
Caldwell et al. | The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis | |
Ye et al. | Effect of aging on the expression of peroxisome proliferator-activated receptor γ and the possible relation to insulin resistance | |
CN106755296B (zh) | Carabin在治疗脂肪肝和Ⅱ型糖尿病中的功能和应用 | |
CN111194724B (zh) | Sh3rf2在制备治疗非酒精性脂肪肝病和/或II型糖尿病的药物中的功能和应用 | |
CN111214660B (zh) | Pax4基因表达抑制剂在制备抑制纤维化的药物中的应用 | |
CN110960538A (zh) | 松果菊苷在治疗糖尿病心肌病中的功能和应用 | |
CN106636353B (zh) | 胱天蛋白酶募集域蛋白6在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 | |
CN106362166B (zh) | 肿瘤坏死因子受体相关泛支架和信号蛋白在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 | |
CN106620723B (zh) | G蛋白信号转导调节蛋白10在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 | |
CN104001188B (zh) | 离心力和剪应力应答基因1在脂肪肝和糖尿病中的功能和应用 | |
CN104056271A (zh) | Tnf受体相关因子5(traf5)在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 | |
CN104069483B (zh) | 肿瘤抑制因子cylindromatosis在治疗脂肪肝和Ⅱ型糖尿病中的功能和应用 | |
CN106498057A (zh) | 三结构域蛋白8在治疗非酒精性脂肪肝和ⅱ型糖尿病中的功能和应用 | |
CN106390141B (zh) | G蛋白信号调节因子6及其抑制剂在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 | |
CN116327939A (zh) | AMPKγ2蛋白用于预防或治疗心肌梗死后心力衰竭的医药用途 | |
CN113812377B (zh) | 一种烧伤合并慢性肾病实验模型的建立方法 | |
CN114557318B (zh) | 一种基于pedf/ldlr双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用 | |
CN108079304B (zh) | Nemo样蛋白激酶在制备治疗Ⅱ型糖尿病药物中的应用 | |
CN106466487B (zh) | 双特异性磷酸酶14在治疗非酒精性脂肪肝和ⅱ型糖尿病中的功能和应用 | |
CN104069510B (zh) | 转录诱导精子形成基因40(Tisp40)在治疗脂肪肝和Ⅱ型糖尿病中的功能和应用 | |
WO2018121409A1 (zh) | Creg在治疗非酒精性脂肪肝和2型糖尿病中的应用 | |
CN106620719A (zh) | 干扰素调节因子1及其抑制剂在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 | |
CN106492229A (zh) | 细胞型Fas相关死亡区域蛋白样β白介素‑1转换酶抑制蛋白在治疗脂肪肝中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200423 Address after: 430072 room 02, 2-3 / F, building B4, phase II, financial backstage service center base construction project, No.77, Guanggu Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province (multiple photos for one site) Applicant after: Wuhan Topaz Intellectual Property Operation Co., Ltd. Address before: 430072 Hubei Province, Wuhan city Wuchang District of Wuhan University Luojiashan Applicant before: WUHAN University |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200610 Address after: 430000 16 / F, building 02, phase III, software new town, No.8 Huacheng Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Applicant after: Wuhan huikangda Technology Co.,Ltd. Address before: 430072 room 02, 2-3 / F, building B4, phase II, financial backstage service center base construction project, No.77, Guanggu Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province (multiple photos for one site) Applicant before: Wuhan Topaz Intellectual Property Operation Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |